On January 14, 2026, the National Tariff Commission of Pakistan issued an updated announcement on Case No. ADC68, making an affirmative final determination on antidumping of cefadroxil originating in or imported from China, and deciding to impose antidumping duties on the products in question.

Specifically, the anti-dumping duty is 8.61% for the manufacturer/exporter, Zhejiang Anglikang Pharmaceuticals Co., Ltd., and 11.81% for other Chinese manufacturers/exporters. This measure is effective from September 17, 2025, and is valid for five years. This case involves products under Pakistani tariff code 2941.9090, which are used to treat bacterial infections such as skin, throat, tonsil, and urinary tract infections. Products in question that are raw materials for export only, used in foreign aid projects, or fall under any export or foreign aid project duty-free schemes stipulated in the Customs Act 1969 are not subject to anti-dumping duties.

On May 21, 2025, Pakistan initiated an anti-dumping investigation into cefadroxil originating in or imported from China. The dumping investigation period was from January 1, 2024 to December 31, 2024, and the injury investigation period was from January 1, 2022 to December 31, 2024. On September 17, 2025, Pakistan issued a preliminary affirmative determination, imposing a provisional anti-dumping duty of 21.64% on the products in question, with the measure effective for four months.